arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Erasca, Inc.

ERAS
$15.54 ▲ +0.52 (+3.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Erasca, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -10.4%
FCF / Share $-0.09
Trailing P/E
Price / Book 13.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-183.44M
↓ -492.4%
FCF / Share Free cash flow per share
$-0.09
↑ +2.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
20
Cash Quality
52

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters